Duramesh™ Mesh Suture
Think Beyond the Common Thread
Problem
Duramesh® Suture was developed to address one of surgery’s most persistent challenges: suture pull-through. Under tension, conventional sutures can concentrate force along a narrow contact area, causing them to cut through the very tissues they are intended to secure. This tissue damage can compromise wound healing and contribute to complications such as wound dehiscence, incisional hernias, and hernia recurrence.
Despite advances in surgical techniques, closure-related complications remain a significant clinical challenge. Published studies have reported incisional hernia rates ranging from 22% to 52% within one to three years following abdominal surgery, while hernia recurrence remains a common long-term concern. These outcomes highlight the need for innovations in suture design that can better distribute forces across tissue and support more durable repairs.
Solution
Developed by Mesh Suture, Inc. (MSi), Duramesh® Suture is a permanent implantable closure device composed of multiple fine filaments loosely braided and bonded to create a large-pore linear mesh attached to a surgical needle. Representing a fundamentally new approach to suture design, it is one of the few major structural innovations in wound closure technology since the earliest sutures were used in antiquity.
Duramesh® minimizes tissue damage by distributing tension along the incision line and diffusing stress at the suture-tissue interface. Its large-pore architecture promotes rapid tissue ingrowth, with tissue integration beginning within days to create a stronger, more durable repair compared with conventional sutures.
With a broad general suture indication, Duramesh® is used in the repair of muscle, fascia, and tendons across a wide range of surgical specialties.
Duramesh is poised to become the standard of care for soft tissue closure within five years, driven by clinical evidence showing its suture reduces early complication rates by up to 90% compared to conventional treatments.”
— Greg Dumanian, MD
Professor, Feinberg School of Medicine
Chief Medical Officer, Mesh Suture Inc.
Benefits
- Immediate Strength: Duramesh evenly distributes tension along the incision and diffuses stress at the suture-tissue interface to support wound healing. By minimizing tissue damage and suture pull-through, it may help reduce the risk of dehiscence compared with standard sutures.
- Long-Term Durability: Duramesh promotes tissue integration for a stronger repair and has been shown to achieve twice the repair strength of a standard suture repair as early as eight days post-operatively.
- Fewer Complications: Early clinical outcomes have demonstrated lower rates of surgical site infection, chronic draining knot sinus, and dehiscence compared with published rates for standard sutures.
- Less Invasive: Duramesh requires less tissue dissection and leaves behind less implanted material than traditional mesh-based approaches, potentially reducing tissue trauma and the risk of surgical complications.
Technology & Commercialization Status
Duramesh® originated from the work of Feinberg's Dr. Gregory Dumanian who developed the technology to address one of surgery’s most persistent challenges: suture pull-through and the tissue damage associated with conventional sutures. His innovation reimagined the structure of the suture itself, creating a large-pore mesh architecture designed to distribute forces more evenly across tissue and promote stronger, more durable repairs.
To translate this innovation into clinical practice, Mesh Suture, Inc. (MSi) was formed to advance the development, manufacturing, and commercialization of Duramesh®. Building on the original invention, the company developed proprietary braiding technologies and manufacturing processes capable of producing the device’s unique mesh structure at commercial scale, while establishing a substantial intellectual property portfolio encompassing nearly 100 patents and trademarks.
Duramesh® received CE Mark approval in 2021 and FDA clearance in 2022, enabling commercialization in both international and U.S. markets. Today, the technology is marketed across four continents and is used in a broad range of procedures involving the repair of muscle, fascia, and tendons.
Northwestern Inventor
Gregory A. Dumanian, MD
Stuteville Professor of Surgery
Feinberg School of Medicine
Links
Website: www.meshsuture.com